How to Stop Lunesta (Eszopiclone)
After short-term use (1-2 weeks), eszopiclone can be discontinued abruptly without tapering, but after medium- to long-term use (>2 weeks), gradually taper the dose by 10-25% weekly to minimize withdrawal symptoms. 1
Discontinuation Strategy Based on Duration of Use
Short-Term Use (≤2 weeks)
- Abrupt discontinuation is safe - no tapering required 1
- Eszopiclone does not produce significant withdrawal symptoms after brief use
- Studies show no evidence of rebound insomnia in the first 3 nights after stopping (sleep onset latency change: 17 minutes, not statistically significant; wake after sleep onset: -6.71 minutes, not significant) 2
Medium- to Long-Term Use (>2 weeks)
Gradual tapering is recommended:
- Reduce dose by 10-25% per week 1
- For high-dose use (≥2/3 of maximum dose) or prolonged use (≥1 year), use a longer, slower taper 1
- Most patients successfully discontinue: 51% took zero capsules during a 2-week discontinuation period, and among those who continued, median use was only 3 capsules over 14 nights 3
What to Expect During Discontinuation
Withdrawal Symptoms
- Low incidence: Only 10.5% of patients experienced clinically relevant withdrawal symptoms after 24 weeks of use 4
- CNS and benzodiazepine-related withdrawal adverse events occur at similar rates to placebo (8.8% vs 9.8%) 5
- No rebound insomnia documented in controlled studies 5, 6
Risk Factors for Difficult Discontinuation
Two groups have more difficulty stopping:
- Patients with hyperarousal (in addition to insomnia) 3
- Patients with dependence behaviors and poor compliance during treatment - these factors predict withdrawal symptoms (odds ratio: 1.650) 4
Practical Tapering Approach
Week-by-week reduction example for 3 mg dose:
- Week 1-2: 2.25 mg (25% reduction)
- Week 3-4: 1.5-1.75 mg
- Week 5-6: 1 mg
- Week 7-8: 0.5 mg or every-other-day dosing
- Week 9: Discontinue
For 2 mg dose:
- Week 1-2: 1.5 mg
- Week 3-4: 1 mg
- Week 5-6: 0.5 mg or every-other-day
- Week 7: Discontinue
Adjunctive Strategies
Pharmacological Support
- Daridorexant (orexin receptor antagonist) can be used with overlapping administration to ease withdrawal from eszopiclone 1
- This newer agent does not produce withdrawal symptoms itself and can bridge the transition
Non-Pharmacological Support
- Cognitive behavioral therapy for insomnia (CBT-I) is strongly recommended as an accompanying treatment during discontinuation (relative risk for success: 1.68) 1
- CBT-I helps maintain sleep improvements after medication discontinuation 5
Key Safety Points from FDA Labeling
The FDA warns about potential risks during use that resolve with discontinuation 7:
- Complex sleep behaviors (sleep-driving, sleep-eating)
- Memory impairment and amnesia
- Next-day psychomotor impairment
- Depression and suicidal thoughts (primarily when combined with other sedatives)
These risks are reasons to discontinue, not barriers to discontinuation.
Common Pitfalls to Avoid
- Don't assume all hypnotics require the same discontinuation approach - eszopiclone has a more favorable withdrawal profile than benzodiazepines
- Don't taper too quickly after long-term use - use slower reductions (10% weekly) for use ≥1 year
- Don't ignore hyperarousal symptoms - these patients need closer monitoring and possibly slower tapers 3
- Don't discontinue without addressing underlying insomnia - implement CBT-I or other non-pharmacological strategies concurrently
Evidence Quality Note
The discontinuation recommendations are based on moderate-quality evidence for short-term outcomes 2 and recent expert consensus for tapering protocols 1. Studies consistently show eszopiclone has minimal withdrawal effects compared to benzodiazepines, with maintained sleep improvements after discontinuation 5, 6.